Molecular characterization of nectin-4 in non-small cell lung cancer subtypes.
Robert Hsu(University of Southern California), Jorge J. Nieva(University of Southern California), Stephen V. Liu(Georgetown University), Matthew J. Oberley(Caris Life Sciences (United States)), C. Patrick(Penn State Milton S. Hershey Medical Center), Nishant Gandhi(Caris Life Sciences (United States)), Balázs Halmos(Montefiore Medical Center), Hirva Mamdani(Wayne State University), Chul Kim(Georgetown University), Ari M. Vanderwalde(West Cancer Center)
Cited by 2
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
|Journal of Hematology & Oncology|2019|634